RBC Capital Cuts United Therapeutics (UTHR) Price Target to $697

RBC Capital maintained its Outperform rating on United Therapeutics Corporation (NasdaqGS: UTHR) on October 22, 2026, while adjusting its price target downward from $708.00 to $697.00. The update arrived alongside active institutional and insider moves as the biotechnology firm prepares for its upcoming financial reporting.

UTHR United Therapeutics Corporation

$586.77 ▲ +18.13% year to date

1M 3M YTD

Daily close · Oct 22, 2026

RBC Capital's Call on United Therapeutics Corporation

In its research note published on October 22, 2026, RBC Capital kept its Outperform rating on the specialty pharmaceutical developer while tweaking the price target to $697.00 from $708.00. The new target sits above the stock's recent trading level, reflecting the firm's ongoing positive stance on the company's therapeutic pipeline.

Other Institutional Activity in United Therapeutics Corporation

Large investment firms continue to adjust their holdings in the drug maker. Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1,634,305,030.00. Renaissance Technologies, LLC reduced its position by 78,271 shares, finishing with 1,708,739 shares valued at approximately $1,005,336,548.00. Jupiter Topco LLC increased its stake by 415,564 shares, reaching 831,129 shares worth about $488,994,726.00.

United Therapeutics Corporation Stock Up 5.7%

Shares of United Therapeutics Corporation traded recently around $563.49 on October 22, 2026, down about 4.2% from the session's close of $588.35. The stock recently traded below its 52-week high of $609.35 and well above its 52-week low of $409.07.

Recent Earnings

United Therapeutics Corporation reported trailing-twelve-month revenue of $3,154,500,096.00 and earnings of $27.89 per share. The company posted a net profit margin of 41.6% alongside a return on equity of 19.3%. The next earnings report is scheduled for October 28, 2026.

Insider Buying and Selling at United Therapeutics Corporation

Chief Executive Officer Martine A. Rothblatt executed a series of share sales in October 2026. On October 13, 2026, the CEO sold 9,500 shares valued at $5,182,414.00. Additional sales of 9,500 shares each followed on October 16, 2026, worth $5,079,275.00, and on October 19, 2026, worth $5,161,576.00. On October 20, 2026, the CEO sold 9,500 shares at an average price of $553.87 under a planned transaction, totaling $5,261,740.30.

Analysts Set New Price Targets

Wall Street firms maintain active coverage on the specialty pharmaceutical developer. BTIG upgraded the stock to a Buy with a $728.00 target on October 1, 2026. Morgan Stanley maintained an Equal-Weight rating and raised its target to $566.00 from $515.00 on October 7, 2026. Leerink Partners maintained an Outperform rating and raised its target to $725.00 from $685.00 on October 19, 2026. Across 14 analyst opinions, the stock carries a consensus buy recommendation with a mean price target of $656.93.

About United Therapeutics Corporation

United Therapeutics Corporation focuses on developing and commercializing specialty pharmaceutical products for patients facing rare and life-threatening medical conditions. The firm works on advanced treatments in areas like pulmonary hypertension and organ manufacturing, positioning its pipeline to address major unmet needs in specialized healthcare markets.

Bottom Line

Investors will watch the upcoming earnings release on October 28, 2026, for further updates on commercial performance and pipeline progress. Monitoring how shares trade relative to analyst targets will remain a key focus for market participants.